WallStreetZenWallStreetZen

NASDAQ: CGEN
Compugen Ltd Stock

$1.87-0.04 (-2.09%)
Updated Jul 16, 2024
CGEN Price
$1.87
Fair Value Price
N/A
Market Cap
$167.38M
52 Week Low
$0.53
52 Week High
$3.03
P/E
N/A
P/B
2.8x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.91
Operating Cash Flow
N/A
Beta
1.46
Next Earnings
Aug 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CGEN Overview

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CGEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CGEN is good value based on its book value relative to its share price (2.8x), compared to the US Biotechnology industry average (6.51x)
P/B vs Industry Valuation
CGEN's short-term assets ($105.57M) exceed its short-term liabilities ($24.63M)
Short-term Liabilities Financials
CGEN's short-term assets ($105.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more CGEN due diligence checks available for Premium users.

Be the first to know about important CGEN news, forecast changes, insider trades & much more!

CGEN News

Valuation

CGEN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0x
Industry
-18x
Market
31.71x

CGEN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.8x
Industry
6.51x
CGEN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CGEN's financial health

Profit margin

Revenue
$2.6M
Net Income
-$7.3M
Profit Margin
-284%

Assets to liabilities

Assets
$113.7M
Liabilities
$54.0M
Debt to equity
0.91
CGEN's short-term assets ($105.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CGEN's short-term assets ($105.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CGEN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A

CGEN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CGEN$167.38M-2.09%N/A2.80x
ACHV$166.56M-2.02%-3.82x3.37x
IVVD$165.85M+7.75%-0.74x0.93x
ZURA$165.66M+2.98%-2.75x2.72x
KOD$170.21M+9.46%-0.73x0.71x

Compugen Stock FAQ

What is Compugen's quote symbol?

(NASDAQ: CGEN) Compugen trades on the NASDAQ under the ticker symbol CGEN. Compugen stock quotes can also be displayed as NASDAQ: CGEN.

If you're new to stock investing, here's how to buy Compugen stock.

What is the 52 week high and low for Compugen (NASDAQ: CGEN)?

(NASDAQ: CGEN) Compugen's 52-week high was $3.03, and its 52-week low was $0.53. It is currently -38.28% from its 52-week high and 252.83% from its 52-week low.

How much is Compugen stock worth today?

(NASDAQ: CGEN) Compugen currently has 89,505,618 outstanding shares. With Compugen stock trading at $1.87 per share, the total value of Compugen stock (market capitalization) is $167.38M.

Compugen stock was originally listed at a price of $11.12 in Aug 11, 2000. If you had invested in Compugen stock at $11.12, your return over the last 23 years would have been -83.18%, for an annualized return of -7.46% (not including any dividends or dividend reinvestments).

How much is Compugen's stock price per share?

(NASDAQ: CGEN) Compugen stock price per share is $1.87 today (as of Jul 16, 2024).

What is Compugen's Market Cap?

(NASDAQ: CGEN) Compugen's market cap is $167.38M, as of Jul 17, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Compugen's market cap is calculated by multiplying CGEN's current stock price of $1.87 by CGEN's total outstanding shares of 89,505,618.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.